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oEnveloped animal viruses enter cells via a series of
steps that ultimately result in a fusion reaction between
the viral membrane and that of the host cell (Hernandez
et al., 1996). Discoveries over the past 4 years have
revealed the identities and in some cases the structures
of the proteins involved in entry of human immunodefi-
ciency virus type 1 (HIV-1) at the plasma membrane.
Each step of the entry process provides information on
viral tropism and pathogenesis, and each step is a real
or potential target for antiretroviral agents. The rapid
expansion of the AIDS pandemic, the high cost and side
effects associated with highly active antiretroviral ther-
apy, and the emergence of drug-resistant virus strains
call for the development of new interventional strategies.
Virus entry is a particularly attractive target since it in-
volves the exposure, at least transiently, of highly con-
served domains in Env and depends on cell surface
receptors that can be targets for orally available small
molecule inhibitors. Therefore, greater understanding of
the entry process can have very practical benefits in
addition to elucidating factors that impact viral tropism
and pathogenesis.
While the molecules involved in HIV-1 entry have been
identified, it is clear that there is much more to viral entry
than the mere presence of the appropriate receptors on
the surface of a target cell. For example, macrophages
are an important target cell type in vivo, and they express
sufficient levels of the viral CD4 receptor as well as the
two major HIV-1 coreceptors, CCR5 and CXCR4 (Lee et
l., 1999b). However, not all virus strains that require
XCR4 to enter cells can infect macrophages (Rana et
l., 1997; Schmidtmayerova et al., 1998; Simmons et al.,
998; Yi et al., 1998). It is not clear why some viruses can
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229tilize CXCR4 expressed on macrophages whereas oth-
rs cannot. There are other examples of restricted viral
ntry in either cell lines or primary cell types in which
iruses fail to enter cells even though the receptors
eeded for the membrane fusion reaction are present
Bazan et al., 1998; Dittmar et al., 1997; McKnight et al.,
997; Moriuchi et al., 1997; Schmidtmayerova et al., 1998;
Verani et al., 1998; Yi et al., 1998). In addition, there are
xamples in which increased viral pathogenicity has
een associated with relatively subtle changes in the
iral envelope (Env) protein, though the mechanisms that
ccount for this are not readily apparent (Cayabyab et al.,
999; Karlsson et al., 1998; Liu et al., 1999; Reimann et al.,
996). Other Env proteins have been described that ap-
ear to cause membrane fusion more efficiently than
ther closely related Env proteins (Etemad-Moghadam et
al., 2000; Shieh et al., 2000). The mechanisms for this are
also not clear. In this review, I will discuss recent studies
that indicate ways in which viruses may differ from one
another in the entry process while essentially using the
same molecules for the membrane fusion reaction. Spe-
cifically, there is now evidence that entry mediated by the
HIV-1 Env protein is a highly cooperative process and
that it is affected by receptor density as well as by
Env-receptor affinities. In addition, some viral receptors
exist in antigenically distinct conformations, not all of
which may support virus infection equally well. Thus, it is
necessary to go beyond receptor expression to fully
understand the early steps of HIV-1 infection.
THE PROTEINS INVOLVED IN HIV-1 ENTRY
HIV-1 contains a single type 1 integral membrane
protein termed Env that is responsible for both receptor
binding and membrane fusion. Initially synthesized as a
single polypeptide precursor termed gp160, the protein
undergoes a posttranslational proteolytic cleavage that
generates a gp120 surface subunit that is noncovalently
attached to the gp41 transmembrane domain protein
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230 MINIREVIEW(Wyatt and Sodroski, 1998). Thus, the topology and pro-
cessing of HIV-1 Env is similar to many other viral mem-
brane fusion proteins. While attachment of HIV-1 to the
cell surface can result from interactions with many sur-
face molecules (Geijtenbeek et al., 2000; Mondor et al.,
1998), binding of the gp120 subunit to CD4 is the first
required step of virus infection. However, CD4 binding
alone is not sufficient for virus infection as it does not
trigger the conformational changes needed for mem-
brane fusion. For this to occur, Env must also interact
with a coreceptor. All HIV-1 strains studied to date use
the chemokine receptors CCR5 (R5 strains), CXCR4 (X4
strains), or both molecules (R5X4 strains) as coreceptors
(Alkhatib et al., 1996; Berger et al., 1998; Choe et al., 1996;
eng et al., 1996; Doms et al., 1999; Doranz et al., 1996;
ragic et al., 1996; Feng et al., 1996). R5 virus strains
ypically infect macrophages and primary T-cells, and are
he virus type most commonly transmitted between indi-
iduals. X4 virus strains tend to evolve years after infec-
ion in a subset of individuals as a consequence of
utations in Env, and infect primary T-cells and trans-
ormed T-cell lines (Connor et al., 1997; Scarlatti et al.,
997). Thus, the differential use of the major coreceptors
y virus strains coupled with their patterns of expression
argely explains viral tropism at the level of entry. The
mportance of CCR5 for virus transmission was shown by
he discovery that individuals who lack CCR5 due to a
aturally occurring polymorphism are highly resistant to
irus infection, making this receptor an important drug
arget (Dean et al., 1996; Liu et al., 1996; Samson et al.,
996).
In addition to CCR5 and CXCR4, approximately a
ozen other coreceptors have been identified through
he use of in vitro assays (Choe et al., 1996, 1998; Deng
et al., 1997; Doranz et al., 1996; Edinger et al., 1998;
Farzan et al., 1997; Liao et al., 1997; Reeves et al., 1997;
Rucker et al., 1997; Samson et al., 1998). In general, these
alternative coreceptors are used by only a subset of HIV
or SIV strains, and they tend to support virus infection
less efficiently than the major coreceptors. The in vivo
relevance of the alternative coreceptors is not clear, with
the most telling experiments being those in which virus
strains are examined for the ability to infect CCR5-neg-
ative human PBMC in the presence of CXCR4 antago-
nists (Zhang et al., 1998). With one exception (Sharron et
al., 2000), infection of CCR5-negative human PBMCs by
HIV-1, when it occurs, is dependent upon CXCR4. These
studies argue that none of the alternative coreceptors
are relevant for infection of the most important target cell
types in vivo. The reasons for this are likely to be related
to expression patterns and levels. The APJ coreceptor,
for example, is not expressed at detectable levels on
CD4-positive cells (Puffer et al., 2000). Other receptors
may function only at very high levels of expression that
are not attained in vivo. There is some evidence that the
CCR8 coreceptor may support virus infection of thymo-cytes (Lee et al., 2000), and STRL33 is expressed at
sufficiently high levels on a subset of CD4-positive T-
cells to support virus infection (Sharron et al., 2000).
Nonetheless, identifying and studying alternative core-
ceptors is important because the use of effective CCR5
and CXCR4 antagonists could select for viruses with
unusual receptor usage patterns. In this regard, it is
worth noting that SIV strains isolated from red-capped
mangabeys use CCR2 as their primary receptor, likely
due to the fact that most red-capped mangabeys are
CCR5-negative due to an inactivating polymorphism, pro-
viding a striking example of unexpected coreceptor use
in the face of strong selective pressure (Chen et al.,
1998). Therefore, it is worth determining which alterna-
tive coreceptors are expressed on CD4-positive cell
types at levels sufficiently high to support virus infection.
Finally, it is important to ask if CD4 and an appropriate
coreceptor are sufficient to support Env-mediated mem-
brane fusion. In favor of this argument is the fact that
expression of CD4 and coreceptor in heterologous cell
types, including cells from multiple species, invariably
makes them targets for Env-mediated membrane fusion.
Arguments against this include studies suggesting that
glycosphingolipids may play an important role in the
HIV-1 membrane fusion reaction, though these studies
rely on the use of lipid synthesis inhibitors, making it
difficult to control for nonspecific effects (Hug et al.,
2000). However, the need for specific lipid types in virus-
membrane fusion is not unprecedented. Alphaviruses
have an absolute requirement for both cholesterol and
sphingomyelin in the target membrane (Kielian, 1995). At
present, the role of specific lipids in the HIV-1 fusion
process is simply not well understood. Ultimately, recon-
stitution of the fusion system in artificial membranes will
be required to rigorously address the role of specific lipid
types in the HIV-1 infection process.
PUTTING THE PIECES TOGETHER
A diagram depicting a model for HIV-1 entry is shown
in Fig. 1. CD4 binding triggers conformational changes in
Env that enable it to interact with a coreceptor (Lapham
et al., 1996; Trkola et al., 1996; Wu et al., 1996). The
conformational change appears to result in the formation
or exposure of a highly conserved region in gp120 that
lies between the bases of the V1/2 and V3 loops and that
has been implicated in CCR5 binding (Rizzuto et al.,
1998). Given the highly conserved nature of this region, it
is likely that this domain also interacts with CXCR4.
Coreceptor binding is thought to be the final trigger that
results in dramatic structural rearrangements in the gp41
subunit that lead to membrane fusion. The most widely
accepted model posits that coreceptor binding leads to
the formation of a triple-stranded coiled-coil that enables
the hydrophobic fusion peptide at the amino terminus of
gp41 to insert into the target cell membrane, making
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231MINIREVIEWgp41 an integral component of both the viral and cellular
membranes. The triple-stranded coiled-coil then bends
back on itself, forming a six helix bundle in which the
gp41 fusion peptide and transmembrane domain are at
the same end (Chan et al., 1997; Weissenhorn et al.,
997). A recent study by Melikyan et al. has shown that
t is the transition of gp41 from the coiled-coil to the six
elix bundle that is the proximal cause of membrane
usion (Melikyan et al., 2000). This structural transition
hares much in common with other viral membrane fu-
ion proteins, including those from orthomyxoviruses,
iloviruses, paramyxoviruses, and other retroviruses
Chan and Kim, 1998; Skehel and Wiley, 1998).
TRIGGERING RECONSIDERED
Biological membranes are inherently stable structures
hat are not prone to fusion, and membrane fusion is
ightly controlled with regards to time and place. Clearly,
FIG. 1. Targets of opportunity: Inhibition of HIV-1 entry. Binding of CD
n gp120. This domain and the CD4 binding region in gp120 are poten
nhibited by a variety of small-molecule inhibitors, four of which have
onformational changes in gp41 including the formation of a triple-stra
he transition from the triple-stranded coiled-coil to the six helix bundle
y T20. T20 is a peptide based on the second helical domain of gp41 thairuses have evolved proteins that efficiently overcome
he barriers to membrane fusion. Viral Env proteins ap-
g
tear to exist as metastable structures that, when appro-
riately triggered, undergo a series of conformational
hanges that ultimately result in a significant change in
ree energy (Hernandez et al., 1996). The fusion activity of
any enveloped viruses is triggered by acid pH, which is
rovided by endosomes or lysosomes following internal-
zation of virus through normal endocytic processes (He-
enius et al., 1980). There are several advantages to acid
H-dependent virus entry. First, save for those viruses
hat pass through the gut, the only time a virus will
ncounter an acidic environment is when it is inside a
iable cell, ensuring that fusion does not occur prema-
urely. Second, endosomes and lysosomes are generally
ocated near the center of the cell. By fusing with the
imiting membranes of these organelles, the virus’s ge-
etic material enters the cytoplasm in close proximity to
he nucleus, the immediate destination for most virus
ypes. Third, acidification is likely to be a synchronous
rocess. All viral fusion proteins, whether they are en-
120 leads to exposure of the highly conserved coreceptor binding site
ets for neutralizing antibodies. Binding of gp120 to coreceptor can be
escribed to date. Coreceptor binding is believed to trigger additional
oiled-coil with insertion of the fusion peptide into the cell membrane.
mation is the proximal cause of membrane fusion and can be inhibited
ding to the first helical domain blocks formation of the six helix bundle.4 to gp
tial targ
been d
nded caged by receptor or not, are subjected to acidification at
he same time, increasing the likelihood that a sufficient
232 MINIREVIEWnumber of viral Env proteins will undergo the conforma-
tional changes needed to elicit fusion. The highly coop-
erative nature of the fusion reaction makes this an effi-
cient way in which to insure kinetic as well as spatial
cooperativity: the closely packed viral spike proteins all
undergo appropriate conformational changes within a
short period of time. Indeed, acidification of membrane-
bound influenza virus results in lipid mixing within sec-
onds (Hernandez et al., 1996).
In contrast to acid-activated viruses, viruses that fuse
at neutral pH as a consequence of receptor binding are
subject to a number of potentially rate-limiting steps that
could impact fusion kinetics as well as efficiency, making
this a more asynchronous and perhaps less efficient
process. In the case of HIV-1, this may provide significant
opportunities to develop anti-viral agents that target not
the native viral Env protein, but rather the structural
intermediates of the fusion process. Indeed, a small
peptide inhibitor of the fusion process has already been
tested in vivo with impressive results, indicating that
structural intermediates of the fusion process can be
targeted (Kilby et al., 1998). In addition, some of the
domains in Env involved in membrane fusion are highly
conserved, such as the coreceptor binding site and
some regions in gp41, and so could be targets of neu-
tralizing antibodies. Despite the promise of targeting the
entry pathway, there are many questions that have yet to
be answered. How many receptor binding events, for
example, are needed to activate Env trimers and how
many trimers are needed to form a fusion pore? How
long-lived are the structural intermediates of the fusion
process that are drug targets, and can their appearance
be prolonged? Does coreceptor binding trigger formation
of the triple-stranded coiled-coil, the six helix bundle, or
both? Clarifying the steps of HIV-1 entry can only help in
the design of immunogens and antiviral agents that tar-
get conserved regions of Env that become exposed only
during the process of membrane fusion.
MEMBRANE FUSION IS COOPERATIVE
Membrane fusion elicited by viral Env proteins exhibits
cooperativity at several levels. Cooperativity has been
studied in most detail with the influenza hemagglutinin
(HA), where it is estimated that from 3 to 6 HA trimers are
needed to form a fusion pore (Ellens et al., 1990; Her-
nandez et al., 1996). Since the trimers need to be in close
proximity to each other, spatial cooperativity is also re-
quired. This is clearly not a problem in the context of
virus infection in which the viral spike proteins are
closely packed, but could limit fusion when cell surface
HA proteins mediate fusion with adjoining cells. Indeed,
surface density of spike proteins impacts the efficiency
of membrane fusion. Intratrimer cooperativity also oc-
curs, since it appears that activation of an HA trimer
involves all three subunits simultaneously (Boulay et al.,1988). Finally, as noted above, there is kinetic cooperat-
ivity. Upon acid activation, HA trimers become rapidly
inactivated if membrane fusion does not occur (Hernan-
dez et al., 1996). Thus, to form a fusion pore, a sufficient
number of fusion proteins must be in close proximity, and
they must be triggered to undergo conformational
changes within a kinetic window that is likely to vary
depending on the virus type and perhaps even virus
strain.
Only recently has the role of cooperativity in HIV-1 Env
mediated membrane fusion been addressed. In a recent
study by Kabat and co-workers, the consequences of
coreceptor expression levels on virus infection were
carefully studied (Kuhmann et al., 2000). They found a
nonlinear relationship between CCR5 density and virus
infection, leading to an estimate of 6 CCR5 molecules
being needed to form a fusion pore. While this estimate
depends on several assumptions, the number is cer-
tainly compatible with what is known about influenza
HA-mediated membrane fusion. We have recently inves-
tigated the role of cooperativity in the activation of indi-
vidual HIV-1 Env trimers. Our results indicate that three
CD4 binding events are needed to efficiently activate
HIV-1 Env trimers, consistent with an earlier study by
Layne et al. showing that multimeric CD4 binding is
required for HIV-1 infection (Layne et al., 1990). In addi-
tion, it appears that multiple coreceptor binding events
per trimer are also needed for fusion to occur efficiently.
There are some interesting implications associated
with the requirement for multiple HIV-1 Env trimers, and
multiple receptor binding events, for the membrane fu-
sion reaction. It logically follows that receptor density will
play a role in governing the rate and efficiency of mem-
brane fusion. In addition, since both gp120–CD4 and
gp120–coreceptor binding events are fully reversible, we
hypothesize that Env trimers must simultaneously en-
gage multiple receptors in order to be activated. There-
fore, Env-receptor affinity may also govern the rate and
efficiency of membrane fusion. If true, one consequence
of using coreceptor antagonists is that receptor density
will be reduced, fusion kinetics prolonged, and the struc-
tural intermediates of the fusion process longer lived,
making the virus potentially more susceptible to com-
pounds like T20 as well as antibodies to conserved
regions that are exposed transiently during the fusion
process.
IMPLICATIONS OF COOPERATIVITY:
RECEPTOR DENSITY
If virus entry requires multiple receptor binding events,
it logically follows that receptor density will influence
virus infection. Most in vitro assays that have been used
to assess the types of coreceptors used by virus strains
typically express tens of thousands of copies of CD4,
CCR5, or CXCR4. Under these conditions, receptor den-
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233MINIREVIEWsity is not limiting for virus infection. Primary T-cells and
macrophages, however, typically express fewer than
10,000 copies of CCR5 or CXCR4, with expression levels
being dependent upon the donor and growth conditions
(Lee et al., 1999b). By contrast, CD4 is expressed at
much higher levels, with an average of approximately
65,000 molecules per CD4-positive T-cell (Lee et al.,
999b; Lenkei and Andersson, 1995). Therefore, in the
ontext of the primary cell types most commonly infected
y HIV-1, coreceptor levels are more likely to influence
irus infection than are levels of CD4.
Several studies have investigated the role of corecep-
or expression levels in HIV-1 and SIV infection. Platt et
l. showed that if CD4 is expressed at high levels, very
ow levels of CCR5 and CXCR4 are needed to support
irus infection (Platt et al., 1997). Since CD4 binding
riggers exposure of the coreceptor binding site, high
evels of CD4 might enable Env to interact with CCR5 or
XCR4 more efficiently. Other studies have confirmed
his finding for both HIV-1 and SIV (Edinger et al., 1999;
harron et al., 2000).
While CCR5 and CXCR4 can support virus infection
ven at very low levels of expression, this is not always
rue for alternative coreceptors. In the case of STRL33,
or example, there appears to be a threshold level of
eceptor expression below which infection does not oc-
ur, with the threshold varying for different virus strains
Sharron et al., 2000). Some viruses can use this receptor
nly at expression levels that far exceed those found in
ivo. There is also evidence that CCR3 functions as an
IV-1 coreceptor only at high levels of receptor expres-
ion (Rucker et al., 1997). By contrast, the APJ coreceptor
ehaves like CCR5 and CXCR4 in that it exhibits core-
eptor activity even at low levels of expression (Puffer et
l., 2000). It will be important to determine if other viral
oreceptors function at the low levels of expression
ypically found in vivo, or whether they function only
hen overexpressed.
IMPLICATIONS OF COOPERATIVITY:
RECEPTOR AFFINITY
If multiple receptor binding events are needed to ac-
ivate individual HIV-1 Env trimers, it logically follows that
nvs that exhibit higher affinities for their receptors will
e able to elicit membrane fusion more quickly than Env
roteins that exhibit poor receptor binding. What then is
nown about the affinity of different HIV-1 Env proteins
or CD4 and the coreceptors? In general, it appears that
nv-CD4 binding constants are less variable than Env-
oreceptor binding constants. Env-CD4 affinities are of-
en below 10 nM, though there is some variation (Moore,
990; Moore et al., 1990, 1992). The high resolution struc-
ure of a gp120 core fragment complexed with CD4
hows that many of the contact residues in gp120 are
ighly conserved between divergent virus strains, pro- tiding an explanation for this modest variability (Kwong
t al., 1998).
There is considerable variation between Envs with
egards to coreceptor binding affinities, though it should
e noted that studies in which direct measurements of
p120 binding to CCR5 and CXCR4 have been made are
elatively few in number. Published binding constants for
p120–CCR5 interactions range from approximately 4 to
5 nM (Doranz et al., 1999). In general, it appears that
ddition of soluble CD4 to R5 gp120 proteins results in
eadily detectable binding of the CD4–gp120 complex to
he surface of CCR5-positive cells. By contrast, direct
inding of X4 gp120s to CXCR4 has been very difficult to
etect using equilibrium binding assays (Baik et al., 1999;
oranz et al., 1999). By incorporating CXCR4 into retro-
irus particles and attaching these to the surface of an
ptical biosensor, we were able to study gp120–CXCR4
inding in real time. For the commonly studied gp120
rom the HxB strain, a binding constant of approximately
00 nM was measured, explaining the difficulty in de-
ecting gp120–CXCR4 binding using equilibrium binding
ssays (Hoffman et al., 2000). With these assays, the
apid off-rate exhibited by gp120 results in low or unde-
ectable signals. In addition, R5X4 proteins appear to
nteract weakly with both CCR5 and CXCR4, suggesting
hat a consequence of broadened tropism is reduced
ffinity for both of the major coreceptors (Baik et al.,
999).
Taken together, the binding studies published to date
ndicate that Env-coreceptor binding constants can vary
y two orders of magnitude. Nonetheless, weak core-
eptor interactions are compatible with virus infection in
itro and in vivo, as evidenced by pathogenic X4 and
5X4 SHIV and by the recovery of primary R5X4 and X4
irus strains that bind weakly to coreceptors. Are there
ny practical consequences associated with reduced
oreceptor affinity? It is important to note that while
nv-coreceptor interactions are typically studied with
onomeric gp120, the viral Env is a trimer, each virus
as multiple trimers, and virus is tethered to the cell
urface by high affinity interactions with CD4. Therefore,
he off-rate of gp120 from CXCR4 may have negligible
onsequences in terms of virus dissociation. Where co-
eceptor affinity may be important is when cells have
elatively low levels of coreceptor on the cell surface. If
wo or three simultaneous coreceptor binding events are
eeded to activate a trimer, then a fast off-rate would
ake it less likely that at any give time an Env trimer will
e fully engaged by receptors, reducing the rate of the
onformational change and hence membrane fusion.
VISIBLE AND INVISIBLE RECEPTORS:
RECEPTOR CONFORMATIONThe seven transmembrane domain chemokine recep-
ors transduce information across the plasma membrane
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234 MINIREVIEWupon ligand binding that results in the generation of
specific signaling events. Given this, it is not surprising
the 7TM receptors in general can exist in distinct con-
formational states. The chemokine receptors are no ex-
ception to this, and antigenically distinct conformations
of CCR5 and CXCR4 have been described. In the case of
CXCR4, a panel of monoclonal antibodies was used to
stain various B- and T-cell lines under saturating condi-
tions to measure CXCR4 expression. Though the abso-
lute levels of CXCR4 varied between B-cell lines, there
was no antigenic heterogeneity: each antibody recog-
nized approximately the same level of CXCR4 on a given
cell type. However, on T-cell lines a different pattern
emerged, in which two reactivity patterns were obtained.
One group of antibodies consistently recognized CXCR4
more efficiently than other antibodies regardless of
which T-cell line was examined. These differences in
antibody reactivity were not due to differences in anti-
body affinity for CXCR4, but rather reflected conforma-
tional heterogeneity of CXCR4 in T-cell lines. The same
pattern of reactivity was seen on primary T-cells. Confor-
mational heterogeneity has also been observed for
CCR5, though this does not exhibit the same cell type
dependence as was seen for CXCR4 (Lee et al., 1999a).
The mechanisms responsible for CCR5 and CXCR4
antigenic heterogeneity are not known, nor are the con-
sequences for coreceptor or chemokine receptor func-
tion. Experiments performed to date suggest that post-
translational modifications such as N-linked glycosyla-
tion and sulfation are not responsible for these
differences. It will be interesting to determine if all forms
of CCR5 and CXCR4 can function as chemokine and
coreceptors, and if these differences can help explain
why some viruses can use CXCR4 to infect macrophages
whereas others cannot. One practical consequence of
these findings is that use of a single antibody to study
receptor expression could lead to underestimation of
receptor number. The monoclonal antibody 12G5 is by far
the most commonly used reagent to study CXCR4 ex-
pression, yet this antibody recognizes only a subset of
available CXCR4 conformations on T-cells. Alteration of
receptor conformation represents a potential mechanism
by which small molecules may inhibit coreceptor func-
tion. The first small molecule inhibitor of CCR5, TAK779
(Baba et al., 1999), efficiently blocks HIV-1 infection via
his receptor and blocks gp120–CCR5 binding. However,
recent study by Dragic and co-workers showed that
AK779 binds to a hydrophobic pocket formed largely by
he transmembrane domain regions of CCR5 (Dragic et
l., 2000). Since gp120 binding to CCR5 is mediated by
he amino terminal domain of CCR5 and also by interac-
ions with the extracellular loops (Baik et al., 1999; Dragic
t al., 1998), how then does TAK779 block gp120 binding?
t is intriguing to speculate that TAK779, by binding to this
ydrophobic pocket, alters CCR5 conformation such that
t no longer binds to gp120 or does so poorly. Antibodiesthat recognize specific receptor conformations could po-
tentially be used to determine if TAK779 does in fact alter
CCR5 conformation. In summary, the HIV-1 coreceptors
exist in multiple conformations that could influence viral
infectivity and the use of small molecule inhibitors.
OPPORTUNITIES TO INTERVENE
The viral entry pathway affords many potential oppor-
tunities to block virus infection (Fig. 1). Small molecule
inhibitors of both CCR5 and CXCR4 have been described,
with more under development (Baba et al., 1999; Don-
zella et al., 1998; Doranz et al., 1997; Murakami et al.,
1997; Schols et al., 1997). Given the success of the
pharmaceutical industry in targeting other 7TM recep-
tors and the protection against virus infection afforded by
the D32-ccr5 polymorphism, this is a particularly exciting
area of research. Env can also be targeted. The small
peptide inhibitor T20 prevents conversion of gp41 into
the six-helix bundle conformation and has been shown
to dramatically reduce viral load in vivo (Kilby et al., 1998).
The structure of the gp41 core fragment also reveals the
presence of a hydrophobic pocket that is a potential
target for small molecule fusion inhibitors (Eckert et al.,
1999). Potentially, both the CD4 and coreceptor binding
sites in gp120 could be drug targets as well. Another
approach is to develop immunogens that elicit antibod-
ies to the conserved regions of Env that are involved in
the entry process. The coreceptor binding site in gp120,
the CD4 binding site, and regions in gp41 are all attrac-
tive targets. There is now considerable interest in gen-
erating modified forms of Env that will present these
domains more efficiently. Desrosiers and co-workers
found that eliminating two N-linked glycosylation sites in
the V1/V2 region of SIVmac239 Env resulted in a virus
that was both neutralization sensitive and that also elic-
ited antibodies capable of neutralizing the fully glycosy-
lated parental virus which is otherwise extraordinarily
difficult to neutralize (Reitter et al., 1998). Genetically
triggered forms of Env have been described that are
CD4-independent, being able to interact directly with
either CCR5 or CXCR4 to infect cells (Hoffman et al.,
1999; Kolchinsky et al., 1999; LaBranche et al., 1999). At
least some of these Envs are neutralization sensitive,
suggesting that conserved neutralization determinants
are exposed (Hoffman et al., 1999). Whether genetically
triggered forms of Env or other modified immunogens
will elicit antibodies capable of neutralizing primary iso-
lates is not yet known, but is a promising area of re-
search.
SUMMARY
The identification of the receptors needed by the HIV-1
Env protein to mediate membrane fusion illustrates the
importance of characterizing the entry pathways of vi-
ruses in general. The discovery of the HIV-1 coreceptors
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235MINIREVIEWhas greatly influenced our understanding of viral tropism
and pathogenesis and leads to the identification of ge-
netic factors that influence virus transmission and dis-
ease progression. The challenge for the future will not be
so much to determine which viruses use which recep-
tors, but rather how these receptors are used and how
this correlates with viral tropism and pathogenicity. In-
creased understanding of the entry pathway will also
accelerate development of entry inhibitors, which repre-
sent an entirely new class of antiviral agents. Potentially,
these approaches could be taken for other important
viral pathogens as well.
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